Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.33 |
| ▸ | F7 | P08709 | 1/20 | 0.33 |
| ▸ | F3 | P13726 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28840439 | 0.75 | — | — | |
| SCHEMBL2210108 | 0.74 | TSHR (0.41) | TSHRALDH1A1FAAHTRPV1F7 | |
| SCHEMBL11250695 | 0.74 | TSHR (0.41) | TSHRALDH1A1FAAHTRPV1F7 | |
| SCHEMBL11250699 | 0.74 | TSHR (0.41) | TSHRALDH1A1FAAHTRPV1F7 | |
| SCHEMBL386780 | 0.72 | — | — | |
| SCHEMBL12361650 | 0.72 | — | — | |
| SCHEMBL28887417 | 0.70 | — | — | |
| SCHEMBL13660445 | 0.70 | — | — | |
| SCHEMBL23566850 | 0.69 | FAAH (0.55) | TSHRALDH1A1FAAHTRPV1F7 | |
| SCHEMBL93117 | 0.69 | FAAH (0.55) | TSHRALDH1A1FAAHTRPV1F7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985767-B2 | Glaucoma or ocular hypertension; selective prostaglandin EP2 agonists; carboxy-functional amides or sulfonamide and carboxy bioisosteres thereof; 5-(-3-(N-(4-(1-hydroxyhexyl)phenyl)acetamido)butyl)thiophene-2-carboxylic acid for example | ALLERGAN, INC. (US) | 2011-07-26 | — | — | US | disclosed |
| US-20110172299-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | ALLERGAN, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-7960381-B2 | Substituted gamma lactams as therapeutic agents | ALLERGAN, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110062165-A1 | BALANCED INDIVIDUAL DINING PLATE | ALLERGAN INC | 2011-03-17 | — | — | US | disclosed |
| US-20100093729-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-7592366-B2 | Therapeutic compounds | ALLERGAN, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| US-20090197962-A1 | SUBSTITUTED CYCLOPENTANES HAVING PROSTAGLANDIN ACTIVITY | ALLERGAN, INC. | 2009-08-06 | — | — | US | disclosed |
| US-7507833-B2 | Therapeutic N-aryl or N-heteroaryl pyrazolidine and pyrazolidinone derivatives | ALLERGAN, INC. (US) | 2009-03-24 | — | — | US | disclosed |
| US-20080119539-A1 | THERAPEUTIC AMIDES | ALLERGAN, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080045576-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172299-A1 | THERAPEUTIC SUBSTITUTED CYCLOPENTANES | TUBB6, TUBB3, TUBB2A | TSHR 3912/4885ALDH1A1 587/4885FAAH 1924/4885 |
| US-20080119539-A1 | THERAPEUTIC AMIDES | GOT2, GOT1, ARG2 | TSHR 2420/4885ALDH1A1 357/4885FAAH 81/4885 |
| US-20100093729-A1 | SUBSTITUTED GAMMA LACTAMS AS THERAPEUTIC AGENTS | GLA, GUSB, GANAB | TSHR 4164/4885ALDH1A1 1580/4885FAAH 3019/4885 |
| US-20080045576-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | GOT2, GOT1, NME4 | TSHR 1819/4885ALDH1A1 1555/4885FAAH 3626/4885 |
| US-20090197962-A1 | SUBSTITUTED CYCLOPENTANES HAVING PROSTAGLANDIN ACTIVITY | PTGIS, PTGES, PTGS1 | TSHR 3556/4885ALDH1A1 1258/4885FAAH 220/4885 |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, COXFA4L2 | TSHR 4392/4885ALDH1A1 438/4885FAAH 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.